Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Devastating earthquakes rock Turkey and Syria leaving thousands dead
    • China steps up condemnation of balloon shooting by US
    • China’s military keeps rivals on edge with balloon strategy
    • China sharply rebukes US over decision to shoot down ‘spy’ balloon
    • Ukraine prepares for renewed Russian offensive
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Rothschild family plans to take investment bank private
      • Adani ditched Big Four auditor for UK subsidiaries
      • Carlyle hires ex-Goldman Sachs executive Harvey Schwartz as chief
      • Pension schemes advised to sell LDI funds after gilt chaos
      • World’s biggest gold miner Newmont offers $17bn for rival Newcrest
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news updates from February 6: Quake hits Turkey and Syria, Rothschild family plans bank buyout
      • Pension schemes advised to sell LDI funds after gilt chaos
      • Russia’s budget deficit soars as energy revenues slump by almost half
      • World’s biggest gold miner Newmont offers $17bn for rival Newcrest
      • A bipolar currency regime will replace the dollar’s exorbitant privilege
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • The case for a land value tax is overwhelming
      • Brexit could be reversed — here’s how
      • Pakistan is on the brink
      • How the spy balloon popped a US-China rapprochement
      • The paradox of financial conditions
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Barclays chief: the life lessons I have discovered during cancer treatment
      • Management research: why are so few of its ideas taken up?
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • How long would you wait for a steak?
      • Happy Valley’s classy finale — and the legacy it leaves
      • The menopause makeover
      • After hours with 10 Foot, London’s most notorious graffiti writer
      • The secrets of the Mercedes-Benz Holy Halls
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    David Crow

    US News Editor

    David Crow is the FT's US news editor. His previous roles include US political news editor, coronavirus correspondent, banking editor and senior US business correspondent. He also worked on the main news desk in London. Before joining the FT in 2012, he was managing editor of City AM.
    Email David Crow @bydavidcrow  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Friday, 29 July, 2022
      The Weekend Essay
      A whole new world? Disney after ‘Don’t Say Gay’

      The entertainment giant’s bungled response to a controversial Florida bill has raised difficult questions for its LGBT+ fans

    • Friday, 18 February, 2022
      The Top LineCathie Wood
      Cathie Wood’s breathless promotion of gene editing should worry us all

      Overstating promise of emerging field threatens to skew valuations and progress in biotech sector

    • Friday, 21 January, 2022
      InterviewLunch with the FT
      ‘Shuggie Bain’ author Douglas Stuart: ‘I have a radar for the suffering soul’

      The Booker-winning novelist on the tough Glasgow childhood that inspired the book, and why he writes from love, not anger

    • Thursday, 23 September, 2021
      ExplainerUS tax
      The Biden tax quiz: why it’s so hard to target corporations and the wealthy

      Take our 10-question test to learn more about the revenue raising proposals making their way through Congress

    • Friday, 13 August, 2021
      InterviewLunch with the FT
      Pfizer chief Albert Bourla: ‘We are the most efficient vaccine machine’

      The pharma boss on the Covid jab, his exchanges with Trump — and why suspending patents is no way to inoculate the world’s poor

    • Thursday, 3 June, 2021
      Covid-19 vaccines
      US unveils plan to donate millions of Covid vaccine doses globally

      Biden administration to allocate 25m shots to South America, Africa, and south and south-east Asia

    • Thursday, 13 May, 2021
      FT Magazine
      How mRNA became a vaccine game-changer

      The molecule behind the Pfizer and Moderna jabs has turned the Covid tide. Can it revolutionise medicine?

    • Friday, 23 October, 2020
      US presidential election 2020
      Presidential debate: How our columnists rated the last Trump-Biden battle — as it happened
    • Friday, 9 October, 2020
      News in-depthRegeneron Pharmaceuticals Inc
      Regeneron: the company that Trump claims cured his Covid

      President’s championing of novel therapy thrusts biotech group into uncomfortable spotlight

    • Thursday, 8 October, 2020
      US presidential election 2020
      Vice-presidential debate: read our columnists’ analysis of Harris, Pence and the fly — as it happened
    • Wednesday, 30 September, 2020
      US presidential election 2020
      Presidential debate: our experts’ insights from the Trump-Biden duel — as it happened
    • Thursday, 27 August, 2020
      FT Magazine
      Is this the end for America’s mom-and-pop stores?

      For small family businesses already struggling against retail chains and online giants, Covid-19 threatens to be a fatal blow

    • Monday, 24 August, 2020
      Coronavirus pandemic
      Trump considers fast-tracking UK Covid-19 vaccine before US election

      Move comes as FDA gives emergency authorisation for use of plasma from recovered patients

    • Monday, 24 August, 2020
      FT News Briefing podcast10 min listen
      Trump considers vaccine fast-track, dividends fall, Marble Ridge

      Trump considers fast tracking a UK coronavirus vaccine ahead of the presidential election

    • Thursday, 20 August, 2020
      Coronavirus: free to read
      Why is the ‘anti-vaxxer’ movement growing during a pandemic?

      US concerns that Trump will rush to approve a vaccine before election is playing into wider safety fears

    • Thursday, 6 August, 2020
      Coronavirus pandemic
      The next virus pandemic is not far away

      Scientists say new diseases will jump from animals unless humans change the way they live

    • Wednesday, 5 August, 2020
      Coronavirus treatment
      J&J strikes $1bn Covid-19 vaccine deal with US

      Moderna to sell some doses of its own coronavirus jab candidate for between $32 and $37

    • Wednesday, 22 July, 2020
      ExplainerCoronavirus pandemic
      Test, test, test — but what can America do about the delays?

      Patients in the US are waiting more than a week for results, by which time it’s probably too late

    • Tuesday, 21 July, 2020
      Coronavirus: free to read
      US lab giant warns of new Covid-19 testing crunch in autumn

      Quest Diagnostics executive says ‘no way’ capacity will expand enough to cope with flu season

    • Sunday, 19 July, 2020
      Coronavirus pandemic
      Trump under pressure on test funding as Covid-19 surges

      President says mass testing ‘skews the numbers’ as governors say more money is needed

    • Friday, 17 July, 2020
      News in-depthThe Big Read
      US coronavirus surge: ‘It’s a failure of national leadership’

      Sunbelt states suffer a big rise in cases and deaths amid the growing politicisation of issues such as wearing masks

    • Thursday, 16 July, 2020
      Coronavirus treatment
      Lie on your front: the small things in Covid-19 survival

      Doctors in sunbelt states share lessons learnt from New York in hope of limiting deaths

    • Thursday, 2 July, 2020
      Coronavirus pandemic
      Independence Day: a star-spangled superspreader event

      US public health experts warn of heightened risk of virus transmission during July 4 celebrations

    • Tuesday, 30 June, 2020
      Coronavirus pandemic
      US hospitals buckle under surge of new coronavirus cases

      Intensive care units in parts of Texas and Arizona are operating near full capacity

    • Tuesday, 30 June, 2020
      Coronavirus treatment
      The hedge fund manager behind a long-shot coronavirus pill

      Wayne Holman and his wife Wendy are betting they can change the course of the pandemic

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In